We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · April 28, 2020

Ubrogepant Improved Patient-Reported Functional Disability and Satisfaction



Additional Info

Disclosure statements are available on the authors' profiles:

Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II
Headache 2020 Apr 01;60(4)686-700, DW Dodick, RB Lipton, J Ailani, RB Halker Singh, AR Shewale, S Zhao, JM Trugman, SY Yu, HN Viswanathan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading